Displaying 47 (all) recruiting clinical trials.
-
An Open-label Multicenter Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Amivantamab a Human Bispecific EGFR and cMet Antibody for the Treatment of Subjects with Advanced Non-Small Cell Lung Cancer
The purpose of the study is to determine the safety and antitumor activity of amivantamab delivered subcutaneously (SC) or under the skin with and without ... -
A Phase 1 Open-Label Safety Pharmacokinetic and Preliminary Efficacy Study of STRO-002 an Anti-Folate Receptor Alpha (FolRa) Antibody-Drug Conjugate (ADC) in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
The purpose of the study is to determine the safety and efficacy of STRO-002, which is a antibody drug conjugate (ADC) given intravenously every 3 ... -
A Phase 1 Open-label Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
The purpose of the study is to determine the safety and tolerability of intravenous (IV) administered CLN-049. CLN-049 is a novel BITE therapy that target ... -
A study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)
The purpose of the study is to determine and evaluate the safety, tolerability, and systemic exposure of intravesical enfortumab vedotin. We want to identify the ... -
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb 22841 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors (DUET-4)
The purpose of the study is to assess the safety and tolerability of XmAb®22841 Monotherapy and in Combination with Pembrolizumab. XmAb®22841 is a ... -
A First in Human Study of theMenin-KMT2A (MLL1)Inhibitor JNJ-75276617 in Participants with Acute Leukemia
The primary objectives of this study are to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-75276617, as well as the safety and tolerability ... -
A Randomized Placebo-Controlled Double-Blind Phase 1 Study of ART24 in Subjects Recently Cured of a Clostridioides difficile Infection (CDI)
The purpose of this study is to evaluate the safety and tolerability of ART24 after 28 days of daily administration for subjects who have already ... -
A Phase I First-In-Human Multicenter Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
The purpose of the study is to determine the safety, tolerability, and immunogenicity, and to detect any preliminary evidence of anti-tumor activity of Nous-209 genetic ... -
A Phase I Open-Label Multicenter Study of FT596 as a Monotherapy and in Combination with Rituximab or Obinutuzumab in Subjects with Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia
The purpose of the study is to determine the recommended phase 2 dose for FT596 as monotherapy and in combination with rituximab or obinutuzumab for ... -
A Pilot Randomized Controlled Trial of Integrated Supportive and Nephrology Care versus Usual Care
The purpose of this study is to test the impact of adding a form of care known as palliative, or supportive, care to your usual ...